Nogapendekin Alfa Inbakicept-pmln (Anktiva)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.684 alerts
Get alerted when Policy CP.PHAR.684 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization and medical-necessity requirements for Anktiva administered with BCG for adults with BCG-unresponsive non-muscle-invasive bladder cancer, including initial and continued therapy, dosing, documentation, and coding.
HCPCS code J9028 was added for injection of nogapendekin alfa inbakicept-pmln for intravesical use, billed per 1 microgram.
HCPCS codes J9999 and C9399 were removed from the policy coding references.
The 3Q 2025 annual review recorded no significant changes and updated references while removing irrelevant drugs from the therapeutic alternatives appendix.
An off-label indication was added for Ta/T1 high-grade disease without carcinoma in situ under NCCN guidance.
The policy added an option for treatment to be prescribed by or provided in consultation with a urologist.
The policy added a requirement that the member is not a candidate for cystectomy.
The policy added provider attestation that Adstiladrin therapy was considered and not recommended, with clinical rationale supporting Anktiva over Adstiladrin.
The initial approval duration was extended from 6 months to 12 months.
The covered disease scope was updated for the FDA label expansion to include BCG-unresponsive non-muscle-invasive bladder cancer without carcinoma in situ.
The ICHRA line of business was added during the 3Q 2026 annual review.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.